Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 10/20 | 0.53 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.53 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.53 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL1191171 | 0.99 | SLC22A12 (0.53) | SLC22A12SLC22A6SLC22A8GPBAR1POLB | |
| SCHEMBL1191393 | 0.96 | SLC22A12 (0.50) | SLC22A12SLC22A6SLC22A8GPBAR1POLB | |
| SCHEMBL1191517 | 0.92 | SLC22A12 (0.64) | SLC22A12SLC22A6SLC22A8GPBAR1POLB | |
| SCHEMBL1190918 | 0.89 | SLC22A12 (0.60) | SLC22A12SLC22A6SLC22A8GPBAR1POLB | |
| SCHEMBL1190479 | 0.89 | SLC22A12 (0.63) | SLC22A12SLC22A6SLC22A8GPBAR1POLB | |
| Bromide SCHEMBL1190165 | 0.88 | SLC22A12 (0.61) | SLC22A12SLC22A6SLC22A8GPBAR1POLB | |
| SCHEMBL1191276 | 0.87 | SLC22A12 (0.46) | SLC22A12SLC22A6SLC22A8GPBAR1POLB | |
| SCHEMBL4902036 | 0.86 | POLB (0.58) | SLC22A12SLC22A6SLC22A8GPBAR1POLB | |
| SCHEMBL1191290 | 0.86 | SLC22A12 (0.57) | SLC22A12SLC22A6SLC22A8GPBAR1POLB | |
| SCHEMBL1191396 | 0.85 | SLC22A12 (0.44) | SLC22A12SLC22A6SLC22A8GPBAR1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2266989-B1 | HETEROCYCLIC DERIVATIVES | C & C RES LAB (KR) | 2015-09-02 | — | — | EP | claimed |
| US-8394792-B2 | Heterocyclic derivatives | C&C RESEARCH LABORATORIES (KR) | 2013-03-12 | — | — | US | claimed |
| CN-102015726-A | Heterocyclic derivatives | C & C RES LAB | 2011-04-13 | — | — | CN | claimed |
| US-20110028467-A1 | HETEROCYCLIC DERIVATIVES | C&C RESEARCH LABORATORIES (KR) | 2011-02-03 | — | — | US | claimed |
| EP-2266989-A2 | HETEROCYCLIC DERIVATIVES | C&c Research Laboratories (KR) | 2010-12-29 | — | — | EP | claimed |
| EP-2266989-B1 | HETEROCYCLIC DERIVATIVES | C & C RES LAB (KR) | 2015-09-02 | — | — | EP | disclosed |
| US-8394792-B2 | Heterocyclic derivatives | C&C RESEARCH LABORATORIES (KR) | 2013-03-12 | — | — | US | disclosed |
| US-8394792-B2 | Heterocyclic derivatives | C&C RESEARCH LABORATORIES (KR) | 2013-03-12 | — | — | US | disclosed |
| US-8394792-B2 | Heterocyclic derivatives | C&C RESEARCH LABORATORIES (KR) | 2013-03-12 | — | — | US | disclosed |
| CN-102015726-A | Heterocyclic derivatives | C & C RES LAB | 2011-04-13 | — | — | CN | disclosed |
| US-20110028467-A1 | HETEROCYCLIC DERIVATIVES | C&C RESEARCH LABORATORIES (KR) | 2011-02-03 | — | — | US | disclosed |
| US-20110028467-A1 | HETEROCYCLIC DERIVATIVES | C&C RESEARCH LABORATORIES (KR) | 2011-02-03 | — | — | US | disclosed |
| US-20110028467-A1 | HETEROCYCLIC DERIVATIVES | C&C RESEARCH LABORATORIES (KR) | 2011-02-03 | — | — | US | disclosed |
| EP-2266989-A2 | HETEROCYCLIC DERIVATIVES | C&c Research Laboratories (KR) | 2010-12-29 | — | — | EP | disclosed |
| WO-2009145456-A2 | HETEROCYCLIC DERIVATIVES | 주식회사 씨앤드씨신약연구소 (KR) | 2009-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028467-A1 | HETEROCYCLIC DERIVATIVES | XDH, NUDT1, UGDH | SLC22A12 692/4885SLC22A6 625/4885SLC22A8 119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.